The US biotech’s technology integrates multiple protein modalities to simultaneously target a variety of disease mechanisms.

Variations on the hub-and-spoke model have blossomed in the drug development industry over the past few years — and a new antibody hub is entering the fray.

The US biotech’s technology integrates multiple protein modalities to simultaneously target a variety of disease mechanisms.